Sign in Subscribe
Cancer

Artificial Intelligence Networks Show Promise in Predicting Immunotherapy Outcomes for Gastrointestinal Cancers

Strategic Insights

— 1 min read

A systematic review and meta-analysis of artificial intelligence (AI) networks has shown promising potential in predicting immunotherapy outcomes for gastrointestinal cancers based on genetic mutation features. The study, published in BMC Gastroenterology, analyzed 45 studies involving 14,047 participants and found that AI models were able to predict immunotherapy responses with an accuracy of 82% and a sensitivity of 83%.

The researchers, from the Faculty of Medicine at Istanbul Yeniyuzyil University, used AI networks to analyze genetic mutation profiles and identify patterns that could predict the effectiveness of immunotherapy in gastrointestinal cancers. The study found that AI networks demonstrated promising potential in predicting immunotherapy outcomes, but further large-scale studies are needed to validate AI models and integrate them into clinical practice.

Key Takeaways:

  • The study analyzed 45 studies involving 14,047 participants and found that AI models were able to predict immunotherapy responses with an accuracy of 82% and a sensitivity of 83%.
  • The researchers used AI networks to analyze genetic mutation profiles and identify patterns that could predict the effectiveness of immunotherapy in gastrointestinal cancers.
  • The study found that AI networks demonstrated promising potential in predicting immunotherapy outcomes, especially in gastric cancer models, with an AUC of 0.87.
  • However, further large-scale studies are needed to validate AI models and integrate them into clinical practice.
  • The study's findings have the potential to improve treatment decisions and patient stratification in gastrointestinal cancers.

Statistics:

  • A total of 45 studies were included in the analysis, all published in 2024.
  • The studies involved 14,047 participants in training sets and 10,885 participants in test sets.
  • The pooled results of AI model performance for gastrointestinal cancers based on genetic mutation features were:

+ AUC = 0.86 (95% CI: 0.86-0.87)

+ Sensitivity = 83% (95% CI: 83%-84%)

+ Specificity = 72% (95% CI: 72%-73%)

+ Accuracy = 82% (95% CI: 82%-83%)

  • Heterogeneity was low to moderate, and no publication bias was detected.

Sources:

  • Artificial intelligence networks for assessing the prognosis of gastrointestinal cancer to immunotherapy based on genetic mutation features: a systematic review and meta-analysis. BMC Gastroenterology, 2025;25(1):310.
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England (contact: Bmc - www.biomedcentral.com; BMC Gastroenterology - www.biomedcentral.com/bmcgastroenterol/)
  • Faculty of Medicine, Istanbul Yeniyuzyil University, Istanbul, Turkey (contact: Hesam Mobaraki)

Read more